UFP TechnologiesFRA:UFP -0.55%96 ROC (Joel Greenblatt) % is 41.45% as of Mar. 2026, which is 67% above its 10-year median of 24.89. GuruFocus rates FRA:UFP with a GF Score™ of 96/100 and a GF Value™ of €227.62 (Fairly Valued). The stock has 2 warning signs investors should review. Among 840 Medical Devices & Instruments companies, UFP Technologies ranks better than 86.55% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. UFP Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 41.45%.
The historical rank and industry rank for UFP Technologies's ROC (Joel Greenblatt) % or its related term are showing as below:
FRA:UFP'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 15.14 Med: 24.89 Max: 45.62
Current: 42.51
During the past 13 years, UFP Technologies's highest ROC (Joel Greenblatt) % was 45.62%. The lowest was 15.14%. And the median was 24.89%.
FRA:UFP's ROC (Joel Greenblatt) % is ranked better than 86.55% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 4.24
vs FRA:UFP: 42.51
UFP Technologies's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 20.50% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
UFP Technologies ROC (Joel Greenblatt) % Related Terms
UFP Technologies ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for UFP Technologies's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UFP vs NEOG, ALMR, NVCR: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, UFP Technologies's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UFP Technologies ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, UFP Technologies's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where UFP Technologies's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 41.45% mean?
UFP Technologies (FRA:UFP) has a ROC (Joel Greenblatt) % of 41.45% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on UFP Technologies and its competitors. This is 67% above median its historical median of 24.89. Over the past decade, UFP Technologies' ROC (Joel Greenblatt) % has ranged from 15.14 to 45.62. According to the industry distribution chart, UFP Technologies ranks #113 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 13.5%.
Is UFP Technologies' ROC (Joel Greenblatt) % too high?
UFP Technologies' current ROC (Joel Greenblatt) % of 41.45% is 67% above median its 10-year median of 24.89. Over the past 10 years, this metric has ranged from a low of 15.14 to a high of 45.62. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.24. UFP Technologies' value of 41.45% is 877.6% above this industry median. Based on the distribution chart, UFP Technologies ranks #113 out of 840 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, UFP Technologies has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does UFP Technologies' ROC (Joel Greenblatt) % compare to NEOG and ALMR?
According to the Medical Devices & Instruments industry distribution chart, UFP Technologies ranks #113 out of 840 companies for ROC (Joel Greenblatt) %. This places UFP Technologies in the top 14% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.24. UFP Technologies' value of 41.45% is 877.6% above this benchmark. Historically, UFP Technologies' own ROC (Joel Greenblatt) % has ranged from 15.14 to 45.62 over the past decade. While the company's 10-year median is 24.89 vs. the industry median of 4.24, UFP Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.24, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UFP Technologies's current ROC (Joel Greenblatt) % of 41.45% is 877.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on UFP Technologies and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UFP Technologies's current ROC (Joel Greenblatt) % is 41.45%, which is 67% above median its own 10-year median of 24.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UFP Technologies stock overvalued right now?
Based on GuruFocus' analysis, UFP Technologies (FRA:UFP) is currently considered Fairly Valued. The stock's GF Value™ is €227.62, compared to a current price of €217.40 — trading 4.5% below its estimated fair value. The current ROC (Joel Greenblatt) % is 41.45%, which is 67% above median its 10-year median of 24.89 and 877.6% above the Medical Devices & Instruments industry median of 4.24. UFP Technologies' overall GF Score™ is 96/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For UFP Technologies (FRA:UFP), the current ROC (Joel Greenblatt) % is 41.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UFP Technologies (FRA:UFP) Overvalued in 2026?
Based on GuruFocus' analysis, UFP Technologies stock appears to be undervalued.
The current stock price of €217.40 is trading 4.5% below its estimated GF Value™ of €227.62.
GuruFocus considers UFP Technologies to be Fairly Valued.
Key valuation signals for FRA:UFP:
ROC (Joel Greenblatt) %: 41.45% (67% above median its 10-year median of 24.89)
GF Value™: €227.62 vs. price of €217.40 (4.5% below fair value)
Industry Position: 877.6% above the Medical Devices & Instruments median (#113 of 840)
No single metric tells the full story. See the FRA:UFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UFP Technologies Inc is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. The company manufactures its products by converting raw materials using laminating, molding, radio frequency, and impulse welding, and fabricating manufacturing techniques. It is an important link in the medical device supply chain and a valued outsource partner to many of the top medical device manufacturers in the world. The company's single-use and single-patient devices and components are used in a wide range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging.
96GF Score
Get the complete analysis for FRA:UFP
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UFP has been successfully added to your 
